Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Witt

Showing results (201-210 of 242) with videos related to

Pageof 25
Sort By:
Nature|May 23, 2014
Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencingVolker Hovestadt, David T W Jones, Simone Picelli, et al.
Nature Medicine|March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|April 16, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
NPJ Precision Oncology|December 27, 2022
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORMHeike Peterziel, Nora Jamaladdin, Dina ElHarouni, et al.
Cell|January 24, 2012
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutationsTobias Rausch, David T W Jones, Marc Zapatka, et al.
The Journal of Clinical Investigation|February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastomaLisa Werr, Jana Boland, Josephine Petersen, et al.
Acta Neuropathologica|March 18, 2023
Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusionsHenri Bogumil, Martin Sill, Daniel Schrimpf, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2025
Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicineKarin P S Langenberg, Sander R van Hooff, Bianca Koopmans, et al.
Cancer Research|July 8, 2022
FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional CircuitsJessica W Tsai, Paloma Cejas, Dayle K Wang, et al.
Pageof 25

Showing results (201-210 of 242) with videos related to

Sort By:
Pageof 25
Nature|May 23, 2014
Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencingVolker Hovestadt, David T W Jones, Simone Picelli, et al.
Nature Medicine|March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|April 16, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
NPJ Precision Oncology|December 27, 2022
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORMHeike Peterziel, Nora Jamaladdin, Dina ElHarouni, et al.
Cell|January 24, 2012
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutationsTobias Rausch, David T W Jones, Marc Zapatka, et al.
The Journal of Clinical Investigation|February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastomaLisa Werr, Jana Boland, Josephine Petersen, et al.
Acta Neuropathologica|March 18, 2023
Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusionsHenri Bogumil, Martin Sill, Daniel Schrimpf, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2025
Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicineKarin P S Langenberg, Sander R van Hooff, Bianca Koopmans, et al.
Cancer Research|July 8, 2022
FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional CircuitsJessica W Tsai, Paloma Cejas, Dayle K Wang, et al.
Pageof 25